Heat Biologics and Subsidiary Appoint New Scientific Advisors

Heat Biologics (NASDAQ:HTBX) along with its subsidiary, Pelican Therapeutics announced the appointment of two new members to their each scientific advisory boards.
As quoted in the press release:

Joining the boards are Robert B. Levy, Ph.D., Sylvester Comprehensive Cancer Center at the University of Miami, Miller School of Medicine and Professor of Microbiology & Immunology, Ophthalmology and Medicine; and Robert Negrin, M.D., Division Chief of Blood and Marrow Transplantation at Stanford University.
“We are very pleased to welcome Dr. Levy and Dr. Negrin to our Scientific Advisory Board. These appointments enable us to collaborate with two world-renown experts who are aligned with our immunotherapeutic focus and anticipated clinical programs,” said Jeff Wolf, CEO of Heat.

Click here to read the full press release.

Source: www.accesswire.com